

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 399)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09(1) of the Listing Rules.

The Board wishes to inform the Shareholders and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group, it is expected to record a significant and substantial loss for the year ended 30 June 2012 as compared to the profit recorded for the year ended 30 June 2011.

The information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group, which have not been reviewed, confirmed nor audited by the Company's independent auditors.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by United Gene High-Tech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Based on a preliminary review by the board of directors of the Company (the “**Board**”) of the unaudited consolidated management accounts of the Group, the Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group is expected to record a significant and substantial loss for the year ended 30 June

2012 as compared to the profit of approximately HK\$5.606 million recorded for the year ended 30 June 2011. Based on the relevant information currently available to the Company, the Board considers that such loss was mainly attributable to:

- (1) a significant reduction in turnover;
- (2) significant impairment loss on the intangible asset in the segment “Distribution of gene testing services”;
- (3) a significant impairment loss on an intangible asset and a full goodwill impairment in the segment “Distribution of bio-industrial products”; and
- (4) increasing operating expenses for the start-up of the health care management services centre in the segment “Provision of health care management services”.

As the Company is still in the course of preparing its annual results for the year ended 30 June 2012, the information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group, which have not been reviewed, confirmed nor audited by the Company’s independent auditors. The overall financial results of the Group for the year ended 30 June 2012 will only be ascertained when all the relevant results are finalised. The annual results of the Group for the year ended 30 June 2012 are expected to be announced by the Company by the end of September 2012. Shareholders and potential investors are advised to read the annual results announcement of the Company carefully when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Director

Hong Kong, 19 September 2012

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).

Please also refer to the published version of this announcement on the Company’s website: www.unitedgenegroup.com and www.irasia.com/listco/hk/unitedgene.